deltatrials
Completed PHASE4 NCT00171054

Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension

A Randomized, Double-blind, Parallel Group, Active-controlled, 38-week Study to Evaluate the Efficacy of Valsartan Versus Amlodipine on the Arterial Properties of Postmenopausal Women With Mild to Moderate Hypertension

Sponsor: Novartis

Conditions Hypertension
Interventions Amlodipine 10 mg Hydrochlorothiazide Valsartan 320 mg
Updated 5 times since 2017 Last updated: Jun 2, 2011 Started: Sep 30, 2003 Primary completion: Oct 31, 2007 Completion: Oct 31, 2007

This PHASE4 trial investigates Hypertension and is currently completed. Novartis leads this study, which shows 5 recorded versions since 2003 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Sep 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Basel, Switzerland